Navigation Links
PNNL recognized for transferring innovations to the marketplace
Date:12/20/2012

RICHLAND, Wash. Pacific Northwest National Laboratory has been recognized for creating technologies or processes that can store large amounts of renewable energy until it's needed, fight cancer and detect explosives, and then moving the innovations to the marketplace.

The Federal Laboratory Consortium announced today that the Department of Energy national laboratory in Richland is receiving three 2013 Excellence in Technology Transfer awards. The consortium is a nationwide network that encourages federal laboratories to transfer laboratory-developed technologies to commercial markets. With these awards, PNNL has been honored by the FLC more than any other federal laboratory, collecting 78 awards since the program began in 1984.

The 2013 awards will be presented April 25 at the consortium's annual meeting in Westminster, Colo.

Renewable energy storage batteries

Developing a technology that can smoothly integrate energy from variable and intermittent sources such as wind and solar power onto the electricity grid while maintaining grid stability has proven challenging. But PNNL researchers, with funding from DOE's Office of Electricity, recently made significant progress in improving the performance of "redox flow" batteries, which hold promise for storing large amounts of renewable energy and providing greater stability to the energy grid.

First developed in the 1970s, redox flow batteries have shown promise for renewable energy storage but have been limited in their ability to work well in a wide range of temperatures, their relatively high cost and their limited ability to store energy, otherwise known as energy density. The PNNL-developed system incorporates two novel approaches to overcome the limitations of previous generations of redox flow batteries. The result is a dramatically improved operating range, higher energy density and lower cost for vanadium redox flow batteries.

"Successful commercialization of DOE-sponsored technology development, such as this, is vital for creating the grid of the future, and sustaining U.S. leadership in advanced technology," said Imre Gyuk, energy storage program manager at DOE's Office of Electricity.

License agreements with companies like UniEnergy Technologies LLC in Mukilteo, Wash., are expected to lead to commercial products for utilities, power generators and industry.

Therapeutic delivery agent for treating cancers

PNNL researchers created innovative "radiogel" products that allow medical personnel to deliver higher doses of radiation exactly where needed when fighting cancerous tumors that cannot be surgically removed. The treatment is effective, affordable and minimizes exposure to surrounding healthy tissues and organs.

The PNNL-developed, injectable radiogels allow for the delivery of insoluble yttrium-90 a well-established medical radioisotope with many applications in cancer treatment to a precise location for targeted radiation therapy. The radiogels dissolve and disappear once the yttrium-90 decays.

"This new technology will provide doctors with greater flexibility to safely direct radiation therapy to the interior of tumors, as well as to tumor margins following surgical removal," said Darrell Fisher, who leads PNNL's Isotope Sciences Program. "Commercialization of the new treatment will help make it readily available to patients."

DOE's Office of Science provided funding to support early studies on radiogel material composition. A license agreement with Advanced Medical Isotope Corp. of Kennewick, Wash., has led to further development of radiogel products that will eventually be used to treat cancers of the liver, pancreas, brain, neck, and kidneys.

Next-generation microchip Ion Mobility Spectrometer

Researchers at PNNL and Owlstone Ltd., in Cambridge, England, collaborated over a period of several years to successfully develop new technology with the potential to dramatically improve the ability to detect and identify very small amounts of chemicals, such as those that are telltale signs of hidden explosives or disease-revealing proteins in blood.

The Ion Mobility Spectrometer on a Microchip, or IMS Microchip, overcomes limitations of previous sample analytical instruments by shrinking a key component a channel through which molecules must travel. This advance improves performance by allowing higher electric currents to be effectively utilized in the separations process. The dime-sized chip provides dozens of channels through which ions travel to be separated and identified.

Owlstone scientists provided the microfabrication design and methods lying at the foundation of IMS Microchips, while PNNL provided its capabilities in ion mobility spectrometry and mass spectrometry to improve the detection limits and sensitivity of the next generation of analytical microchips.

The unique expertise and capabilities contributed by PNNL researchers were critical to Owlstone in its efforts to successfully develop a commercial IMS Microchip tailored to meet the needs of the mass spectrometry research community.


'/>"/>

Contact: Greg Koller
greg.koller@pnnl.gov
509-372-4864
DOE/Pacific Northwest National Laboratory
Source:Eurekalert

Related biology news :

1. 60th anniversary of NSF Grad Research Fellowship Program; UM fellow Staatermans video recognized
2. Coral researcher recognized with prestigious award
3. UC Riverside entomologist recognized for research in citrus entomology
4. ONR-funded young innovators recognized by President
5. Micross Components Recognized as Teledyne Electronic Manufacturing Services Manufacturer of the Year
6. Research warns Asia unlikely to achieve climate, poverty goals unless womens rights are recognized
7. Patel recognized with NSF Career Award for computer-modeling research on cell membranes
8. Wake Forest Baptist Medical Center Launches Wake Forest Innovations
9. ESMO 2012 Congress: A path for medical oncology innovations
10. PuraMed BioScience®, Inc., Launches a Marketing Blitz for LipiGesic® M, Its Clinically-Tested Migraine Pain Reliever in the Denver, CO Region to Coincide with the NACDSs Marketplace 2012 Trade Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology: